| |
original article |
Date |
Title |
Authors Max. 6 Authors |
| 1 |
[GO] |
2025―Nov―28 |
Analysis of polypharmacy in older adults pre and post COVID-19 |
Shaminul H. Shakib, Demetra Antimisiaris |
| 2 |
[GO] |
2025―Nov―11 |
Impact of gabapentinoids’ reclassification policy and COVID-19 on gabapentinoids’ utilization pattern and their associated mortality in Scotland and Northern Ireland: a segmental regression analysis |
Abdullah Alrahmani, Mabast Azeez, Sahar Baker, Amanj Kurdi |
| 3 |
[GO] |
2025―Mar―01 |
Impact of COVID-19 pandemic on the prescribing pattern of oral anticoagulants in the English primary care setting: a population-based segmented interrupted time series analysis of over 53 million individuals |
Amanj Kurdi, Abdulaziz Albutti, Omeed Darweesh, Karwan M. Amen, Kirmanj Baker, Hardee Karwi, Brian Godman |
| 4 |
[GO] |
2024―Sep―26 |
Population pharmacokinetics of nirmatrelvir/ritonavir in critically ill Chinese COVID-19 patients and recommendations for medication use: a two-center retrospective study |
Junjun Xu, Jinmeng Li, Meng Chen, Huifang Jiang, Xudong Fan, Yangmin Hu, Haili Shan, Mingdong Yang, Yichao Xu, Yuying Lang, Haibin Dai, Xinjun Cai |
| 5 |
[GO] |
2024―Feb―23 |
Antiretroviral therapy response: exploring the potential influence of SARS-CoV-2 |
Ahmad Z. Al Meslamani |
| 6 |
[GO] |
2023―Oct―06 |
Nirmatrelvir/Ritonavir and molnupiravir: an update on COVID-19 antivirals in the omicron era |
Fatima Faraz, Mohammad Ebad Ur Rehman, Abia Shahid, Muhammad Saqib Ghafoor, Huzaifa Ahmad Cheema |
| 7 |
[GO] |
2023―Feb―02 |
Aminoadamantanes: from treatment of Parkinson’s and Alzheimer’s disease to symptom amelioration of long COVID-19 syndrome? |
Thomas Müller, Peter Riederer, Wilfried Kuhn |
| 8 |
[GO] |
2022―Dec―03 |
Thrombosis with thrombocytopenia after vaccination with the ChAdOx1 nCoV-19 vaccine (Oxford-AstraZeneca): implications of gender-specific tissue-factor gene polymorphisms? |
Raffaella Mormile |
| 9 |
[GO] |
2022―Oct―28 |
The nocebo phenomenon in the COVID-19 pandemic: a nocebodemic effect |
Martina Amanzio, Giuseppina Elena Cipriani, Dimos D. Mitsikostas |
| 10 |
[GO] |
2022―Oct―05 |
Utilizing clinical pharmacology in the drug repurposing arena: a look into COVID-19 |
Rosanna Ruggiero, Nunzia Balzano, Raffaella Di Napoli, Maria Giuseppa Sullo, Francesco Rossi, Annalisa Capuano, Concetta Rafaniello |
| 11 |
[GO] |
2022―Sep―01 |
BNT162b2 mRNA COVID-19 vaccine is safe in a setting of patients on biologic therapy with inflammatory bowel diseases: a monocentric real-life study |
Raffaele Pellegrino, Gianluca Pellino, Lucio Selvaggi, Francesco Selvaggi, Alessandro Federico, Marco Romano, Antonietta Gerarda Gravina |
| 12 |
[GO] |
2022―Aug―26 |
The pharmacology of anticoagulant drug treatment options in COVID-19 patients: reviewing real-world evidence in clinical practice |
Vincenzo Russo, Adriano Caputo, Egidio Imbalzano, Pierpaolo Di Micco, Antonio Frontera, Ambra Uccello, Luana Orlando, Paola Galimberti, Paolo Golino, Antonello D’Andrea |
| 13 |
[GO] |
2022―Aug―26 |
A pharmacometric approach to evaluate drugs for potential repurposing as COVID-19 therapeutics |
Thanaporn Wattanakul, Palang Chotsiri, Ivan Scandale, Richard M. Hoglund, Joel Tarning |
| 14 |
[GO] |
2022―Aug―01 |
Non-viral infections and antimicrobial resistance in the time of COVID-19: what to expect? |
Lyudmila Boyanova, Rumyana Markovska, Ivan Mitov, Raina Gergova |
| 15 |
[GO] |
2022―Jul―19 |
Clinical efficacy of sofosbuvir/daclatasvir in patients with COVID-19: a systematic review and meta-analysis of randomized trials |
Chao-Kun Chen, Teng-Song Weng, Yu-Hung Chen, Jui- Heng Kao, Chien-Ming Chao |
| 16 |
[GO] |
2022―Jul―02 |
The effect of inhaled corticosteroids on the outcomes of patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials |
Chao-Hsien Chen, Cheng-Yi Wang, Ya-Hui Wang, Ching-Yi Chen, Kuang-Hung Chen, Chih-Cheng Lai, Yu-Feng Wei, Pin-Kuei Fu |
| 17 |
[GO] |
2022―Jun―23 |
The impact of the COVID-19 pandemic lockdown measures on the prescribing trends and utilization of opioids in the English primary care setting: segmented-liner regression analysis |
Oula Nawaf Sindi, Faisal Salman Alshaikh, Brian Godman, Amanj Kurdi |
| 18 |
[GO] |
2022―May―17 |
Favipiravir-based treatment for outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials |
Shao-Huan Lan, Chih-Cheng Lai, Shen-Peng Chang, Li-Chin Lu, Shun-Hsing Hung, Wei-Ting Lin |
| 19 |
[GO] |
2021―Aug―17 |
Edoxaban for the treatment of pulmonary embolism in hospitalized COVID-19 patients |
Valerio Langella, Roberta Bottino, Antonio Asti, Giulio Maresca, Gisella Di Palma, Domenico Pomponi, Claudia Sassone, Egidio Imbalzano, Vincenzo Russo |
| 20 |
[GO] |
2021―Jul―30 |
Vaccination and their importance for lung transplant recipients in a COVID-19 world |
Samantha Scharringa, Thijs Hoffman, Diana A. van Kessel, Ger T. Rijkers |
| 21 |
[GO] |
2021―Jul―24 |
Molecular docking and dynamics study to explore phytochemical ligand molecules against the main protease of SARS-CoV-2 from extensive phytochemical datasets |
Shafi Mahmud, Mohasana Akter Mita, Suvro Biswas, Gobindo Kumar Paul, Maria Meha Promi, Shamima Afrose, Robiul Hasan, Sharmin Sultana Shimu, Shahriar Zaman, Salah Uddin, Trina Ekawati Tallei, Talha Bin Emran, Abu Saleh |
| 22 |
[GO] |
2021―Jun―30 |
Tocilizumab for the treatment of non-critical COVID-19 pneumonia: an overview of the rationale and clinical evidence to date |
Grace Kenny, Patrick W. G. Mallon |
| 23 |
[GO] |
2021―Mar―26 |
Exploring the room for repurposed hydroxychloroquine to impede COVID-19: toxicities and multipronged combination approaches with pharmaceutical insights |
Ankit Jain, Shiv Kumar Prajapati, Madhavi Tripathi, Ashok M. Raichur, Jagat R. Kanwar |
| 24 |
[GO] |
2021―Mar―12 |
Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: A review of current evidence |
Sayeeda Rahman, Maria Teresa Villagomez Montero, Kherie Rowe, Rita Kirton, Frank Kunik |
| 25 |
[GO] |
2021―Mar―12 |
Compounds of plants with activity against SARS-CoV-2 targets |
Diorge Jônatas Marmitt, Márcia Inês Goettert, Claudete Rempel |
| 26 |
[GO] |
2021―Mar―08 |
How do nocebo effects in placebo groups of randomized controlled trials provide a possible explicative framework for the COVID-19 pandemic? |
Martina Amanzio, Giuseppina Elena Cipriani, and Massimo Bartoli |
| 27 |
[GO] |
2021―Feb―18 |
Concomitant use of dexamethasone and tetracyclines: a potential therapeutic option for the management of severe COVID-19 infection? |
Harmanjit Singh, Prerna Chauhan, Jasbir Singh, Saurabh Saurabh, CS Gautam, Ashish Kumar Kakkar |
| 28 |
[GO] |
2021―Jan―27 |
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain |
Esther Chamorro-de-Vega, Carmen-Guadalupe Rodriguez-Gonzalez, Silvia Manrique-Rodríguez, Elena Lobato-Matilla, Felix García-Moreno, Maria Olmedo, Rafael Correa-Rocha, Maricela Valerio, Teresa Aldámiz-Echevarria, Marina Machado, Milagros Sancho-Gonzalez, Juan Carlos Lopez-Bernaldo-de-Quirós, Paula Ruiz-Briones, Rosa Romero-Jiménez, Camino Sarobe-González, Alvaro Gimenez-Manzorro, Roberto Collado-Borrell, Cecilia M Fernandez-Llamazares, Jose Luis Revuelta-Herrero, Beatriz Somoza-Fernandez, Sebastian Garcia-Sanchez, Irene Taladriz-Sender, Emilio Bouza, Ana Herranz, Patricia Muñoz, Maria Sanjurjo |
| 29 |
[GO] |
2021―Jan―13 |
SARS-CoV-2 protein drug targets landscape: a potential pharmacological insight view for the new drug development |
Chiranjib Chakraborty, Manojit Bhattacharya, Bidyut Mallick, Ashish Ranjan Sharma, Sang-Soo Lee, Govindasamy Agoramoorthy |
| 30 |
[GO] |
2020―Oct―22 |
Managing blood disorders during the Covid-19 pandemic: current pharmacological insights |
Parathan Karunakaran, Ram Vasudevan Nampoothiri, Kamal Kant Sahu |
| 31 |
[GO] |
2020―Oct―03 |
Combining hydroxychloroquine and minocycline: potential role in moderate to severe COVID-19 infection. |
Shashank Shekhar Gautam, C.S Gautam, Vivek Kumar Garg, Harmanjit Singh |
| 32 |
[GO] |
2020―Sep―08 |
COVID-19 epidemic: a special focus on diagnosis, complications and management |
Leilei Ai, Liyu Jiang, Zhifei Xu, Hao Yan, Peihua Luo, Qiaojun He |
| 33 |
[GO] |
2020―Sep―07 |
Melatonin as a putative protection against myocardial injury in COVID-19 infection |
Fedor Simko, Jaroslav Hrenak, Alberto Dominguez-Rodriguez, Russel J. Reiter |
| 34 |
[GO] |
2020―Aug―14 |
Ongoing non-industry-sponsored COVID-19 clinical trials in the first trimester of the pandemic: significant differences between the European and the USA approaches |
Rafael Dal-Ré |
| 35 |
[GO] |
2020―Aug―04 |
Medication therapy strategies for the coronavirus disease 2019 (COVID-19): recent progress and challenges |
Xiaolei Yang, Ye Liu, Yuping Liu, Qing Yang, Xubo Wu, Xuan Huang, Huijia Liu, Weimin Cai, Guo Ma |
| 36 |
[GO] |
2020―Jul―30 |
Development and progress of clinical trials of Coronavirus Disease 2019 antiviral drugs |
Wenyuan Pang, Qiaoyu Wang, Zhigang Zhao |
| 37 |
[GO] |
2020―Jul―18 |
Could a specific ACE2 activator drug improve the clinical outcome of SARS-CoV-2? A potential pharmacological insight |
Lucas A D Nicolau, Isabela R S G Nolêto, Jand V R Medeiros |
| 38 |
[GO] |
2020―Jun―15 |
Contraception and reproductive planning during the COVID-19 pandemic. |
Edson Santos Ferreira-Filho, Nilson Roberto de Melo, Isabel Cristina Esposito Sorpreso, Luis Bahamondes, Ricardo dos Santos Simões, José Maria Soares-Júnior, Edmund Chada Baracat |
